Siemens Healthineers Stock Before Q4: Spin-Off, Ultrasound Exit, Buyback
Siemens Healthineers stock (XETRA: SHL) heads into its quarterly report with three themes in focus. Siemens AG plans to hand 30% of Healthineers shares to its own shareholders. Healthineers stopped selling general-imaging ultrasound systems on 12 October. A €230m buyback is also running. The next test is the Siemens Healthineers Q4 results on 5 November 2026.
The shares closed at €41.86 on Friday 23 October 2026 (17:35 CEST, 16:35 BST). That left them down 6.8% year to date against the 2025 close of €44.92, according to Stooq and MarketScreener. The loss was about 11% in mid-October. A rally of roughly 10% over the past month has narrowed it.
The information in this article is provided for educational purposes only and does not constitute financial advice. Consult a financial advisor before making investment decisions.
Table of Contents
- Siemens Healthineers Stock at a Glance
- Why Is Siemens Healthineers Stock Down This Year?
- Five-Year Performance of SHL Stock
- The Siemens Healthineers Spin-Off Explained
- The Siemens Healthineers Ultrasound Exit
- The Siemens Healthineers Share Buyback
- Fundamentals: Q3 FY2026 Results and Guidance
- Siemens Healthineers Q4 Results Preview
- Siemens Healthineers Price Target and Analyst Ratings
- Siemens Healthineers Technical Analysis
- Siemens Healthineers Stock Forecast 2026: Illustrative Scenarios
- Key Risks for SHL Shareholders
- Dividend and Income Facts
- Key Dates for Siemens Healthineers Stock
- How to Trade Siemens Healthineers Stock: Approaches and Risks Around Earnings
- Summary
- Frequently Asked Questions
Siemens Healthineers Stock at a Glance
The table below gathers the main market data for SHL stock as of the last Xetra close. All prices are in euros.
| Metric | Value | Time or date |
|---|---|---|
| Last price (Xetra close) | €41.86 (+0.24% on the day) | 23 Oct 2026, 17:35 CEST |
| Day range | €41.40 to €41.96 | 23 Oct 2026 |
| Volume | 1.17m shares | 23 Oct 2026 |
| Year to date | -6.8% (from €44.92) | 23 Oct 2026 |
| 52-week range | €32.81 to €49.71 | 23 Oct 2026 |
| Market cap | about €47.2bn (1.128bn shares) | 23 Oct 2026 |
| Dividend for FY2025 | €1.00 per share | Paid February 2026 |
| Next results | Q4 and FY2026, plus FY2027 outlook | 5 Nov 2026 |
Source: Stooq, Siemens Healthineers IR, Siemens Healthineers financial calendar. Market cap is our calculation from the share count and the close. Past performance is not a reliable indicator of future results.
Key points for readers in a hurry:
- The stock hit about €32.8 in May 2026 after a guidance cut and has recovered about 28% since then.
- Siemens AG owns about 67% and wants to distribute 30 percentage points of that stake to its own shareholders.
- Siemens shareholders are due to vote on the plan at the Siemens AGM in February 2027.
- The ultrasound exit covers a unit with just over €600m of revenue in 2025.
- The buyback serves employee share plans and had bought 3.47m shares by 11 October.
- Analysts on TipRanks see an average target of €45.71, though forecasts are not a reliable indicator of future performance.
Why Is Siemens Healthineers Stock Down This Year?
The Siemens Healthineers share price started 2026 at €44.92. It fell to a multi-year low in May. Weak diagnostics and a cautious revenue outlook weighed on it. Worries about the Siemens spin-off added to the pressure.
Revenue Guidance Was Cut Twice
The company began FY2026 with a target of 5% to 6% comparable revenue growth, as its Q4 FY2025 release showed. In May it cut the range to 4.5% to 5.0%, Reuters reported. In July it cut again to 3.5% to 4.0%.
The earnings side moved the other way. Adjusted EPS guidance rose to €2.35 to €2.45 in July. Most of that rise came from refunds of US tariffs, according to the Q3 FY2026 earnings release.
Diagnostics and China
Diagnostics is the weakest unit. In Q2 its comparable revenue fell 6.5% to €985m. CEO Bernd Montag called it "a bit of a perfect storm" on the Q2 call, as Reuters reported.
China is about 10% of group revenue. Management said on the Q3 call that the Chinese diagnostics market has shrunk by about 40% in two years. China revenue fell 10% in Q3, according to GuruFocus call highlights.
Tariffs and the Euro
US tariffs were a major cost risk for FY2026. Refunds of IEEPA tariffs then lifted Q3 profit, according to the Q3 FY2026 release. A US Section 232 investigation into medical devices is still open, as MichBio noted. That keeps the Siemens Healthineers tariff impact on the risk list.
A strong euro also hurts. The US accounts for about 36% of sales, according to MarketScreener, so a weaker dollar cuts the value of US revenue in euros.
The 2026 Path in Numbers
| Date (2026) | Event | Close |
|---|---|---|
| 13 March | New 52-week low at the time | €38.70 |
| 7 May | Q2 results and guidance cut | just under €34 |
| May | Six-year-plus low | about €32.8 (intraday low) |
| 31 July | Q3 results, EPS guidance raised | about €37 |
| 2 October | Stock down 16% year to date | €37.92 |
| 13 October | Stock down 11% year to date | €39.85 |
| 23 October | Latest close | €41.86 |
Source: Börse Express, Börse Express, trading-treff, Stooq. Past performance is not a reliable indicator of future results.
Five-Year Performance of SHL Stock
A longer view helps put the 2026 moves in context. The May 2026 low of about €32.8 was roughly half the 2021 year-end close of €65.82.
| Year | Year-end close (Xetra) | Annual change |
|---|---|---|
| 2021 | €65.82 | +56.8% |
| 2022 | €46.73 | -29.0% |
| 2023 | €52.60 | +12.6% |
| 2024 | €51.20 | -2.7% |
| 2025 | €44.92 | -12.3% |
| 2026 to 23 Oct | €41.86 | -6.8% |
Source: Yahoo Finance, SHL.DE historical prices, period 1 January 2021 to 23 October 2026. Changes are price only and exclude dividends. Past performance is not a reliable indicator of future results.
The table shows two strong years and three weak ones. Over the full period, the share price is lower than at the end of 2020, when it closed at €41.98.
The Siemens Healthineers Spin-Off Explained
The Siemens Healthineers spin-off is the biggest structural change since the 2018 listing. It decides who will own the shares and how many may come to the market.
What Siemens Has Announced
On 12 November 2025 Siemens said it intends to deconsolidate Healthineers. Its preferred route is a direct spin-off of 30% of Healthineers shares to Siemens shareholders, as its ad hoc release stated. The medium-term goal is a purely financial holding.
In April 2026 Siemens set the vote for its ordinary AGM in February 2027, according to its 17 April press release. On 6 August Siemens CFO Veronika Bienert said the tax questions had been clarified with the authorities, AWP reported. Siemens will also cut its seats on the Healthineers supervisory board from three to one.
| Date | Step |
|---|---|
| 12 Nov 2025 | Siemens announces plan to deconsolidate Healthineers |
| 17 Apr 2026 | Vote set for the February 2027 Siemens AGM |
| 6 Aug 2026 | Tax questions clarified with the authorities |
| 12 Nov 2026 | Siemens annual results, with more spin-off detail promised |
| 11 Feb 2027 (to be confirmed) | Siemens AGM votes on the spin-off |
| 18 Feb 2027 | Healthineers AGM, two Siemens board members step down |
Source: Siemens AG, VZ/AWP, Siemens IR calendar, Siemens Healthineers IR.
Who Owns Siemens Healthineers Stock?
The Siemens AG stake in Siemens Healthineers is about 67% today. After a 30-point spin-off it would fall to about 37%. The figures below are our approximate calculation from the announced plan.
| Holder | Before spin-off | After spin-off (approx.) |
|---|---|---|
| Siemens AG | about 67% | about 37% |
| Siemens shareholders (direct) | 0% | about 30% |
| Other free float | about 33% | about 33% |
| Shares that change hands | about 338m |
Source: Siemens AG ad hoc release. Post-spin-off shares are our calculation (30% of 1.128bn shares).
What the Spin-Off Could Mean for Shareholders
Markets read the plan in two ways. A larger free float could raise index weight and trading volume. At the same time, about 338m shares would land with investors who did not choose to own a medtech stock. Berenberg cited "possible share sales by Siemens AG" when it moved to Hold in July, finanztrends reported.
| Potential positives | Potential negatives |
|---|---|
| A larger free float may attract more index and fund demand | New holders may sell shares they did not choose |
| Less influence from a controlling parent | Siemens could sell part of its remaining 37% stake |
| A possible end to any conglomerate discount | Healthineers must refinance about €14.3bn owed to the Siemens Group |
| More board independence from February 2027 | Separation costs of about €50m a year |
Source: Q3 FY2026 release, GuruFocus.
Admirals has also covered the parent company in its Siemens stock forecast, which looks at the deal from the Siemens side.
The Siemens Healthineers Ultrasound Exit
The Siemens Healthineers ultrasound exit took effect on 12 October 2026. It is a stop to new sales in one product line. The company has kept the business for procedures.
What Stops and What Stays
| Discontinued (new sales) | Continued |
|---|---|
| Acuson Sequoia | Acuson Origin (cardiovascular) |
| Acuson Redwood | P500 intracardiac echo (ICE) |
| Acuson Juniper | Acuson Freestyle |
| Acuson Maple | Service, software updates and transducers for installed systems |
Source: Siemens Healthineers press release, 12 October 2026.
The release said general imaging is a well-served market with several established providers. Head of Ultrasound Sourabh Pagaria said imaging is increasingly becoming part of therapy, according to the press release. The focus now is on electrophysiologists and interventional cardiologists.
Why It Matters for the Numbers
Total ultrasound revenue was just over €600m in 2025, trading-treff reported, citing Reuters. That is about 2.6% of group revenue of €23.4bn. The company has not published a restructuring charge for the step.
The exit may simplify the portfolio. It also reduces scale in a unit that sits in the Siemens Healthineers precision therapy segment, according to the Capital Markets Day 2025 release. The Q4 release may show the first effects.
The Siemens Healthineers Share Buyback
The Siemens Healthineers share buyback runs alongside the spin-off. Its purpose is modest. The shares go to employee share plans and share-based pay.
| Term | Detail |
|---|---|
| Announced | 26 May 2026 |
| Maximum volume | €230m |
| Maximum shares | 14m (about 1.2% of shares) |
| Period | 1 June 2026 to 29 January 2027 |
| Venue | Xetra only, via a bank |
| Purpose | Employee share programmes and share-based remuneration |
Source: Deutsche Börse / EQS announcement, Siemens Healthineers IR.
Shares Bought So Far
| Report date (2026) | Cumulative shares bought |
|---|---|
| 28 June | 1.92m |
| 19 July | 2.60m |
| 9 August | 2.77m |
| 27 September | 3.37m |
| 11 October | 3.47m |
Source: 4th interim report, 7th interim report, finanztrends, trading-treff. Past performance is not a reliable indicator of future results.
By 11 October the company had used about 25% of the 14m share cap. Buybacks have run in most years since 2018, as the IR share page lists. For background on the trade-off, see this Admirals guide to share buybacks versus dividends.
The buyback has absorbed about 0.3% of the share count so far. A spin-off that could move about 30% of the shares to new holders is a far larger supply question.
Fundamentals: Q3 FY2026 Results and Guidance
The fiscal year ends on 30 September. Q3 covered April to June 2026.
Q3 FY2026 Key Figures
| Metric | Q3 FY2026 |
|---|---|
| Revenue | €5,764m |
| Comparable revenue growth | +2.8% |
| Adjusted EBIT margin | 19.1% (15.4% excluding tariff refunds) |
| Adjusted EPS | €0.70 (consensus about €0.53) |
| Free cash flow | €1,023m |
| Equipment book-to-bill | 1.27 |
Source: Siemens Healthineers Q3 FY2026 earnings release, GuruFocus. Past performance is not a reliable indicator of future results.
Montag said "we showed great order momentum" in the Q3 earnings release. The book-to-bill above 1 supports that view.
Segment Picture
| Segment | Q3 comparable growth | Note |
|---|---|---|
| Imaging | +2.3% | Margin 26.5% |
| Precision Therapy | +9.2% | Varian +9.3% |
| Diagnostics | -5.5% | Margin 4.1% |
Source: Q3 FY2026 earnings release. Past performance is not a reliable indicator of future results.
How the FY2026 Guidance Changed
| Date | Comparable revenue growth | Adjusted EPS |
|---|---|---|
| 5 Nov 2025 (initial) | 5% to 6% | €2.20 to €2.40 |
| 7 May 2026 | 4.5% to 5.0% | €2.20 to €2.30 |
| 31 Jul 2026 | 3.5% to 4.0% | €2.35 to €2.45 |
Source: Q4 FY2025 release, Reuters via MarketScreener, Q3 FY2026 release. Forecasts are not a reliable indicator of future performance.
At €41.86 the stock trades at about 17.4 times the midpoint of the FY2026 adjusted EPS guidance range. That is our calculation. The Admirals guide to the price-to-earnings ratio explains how traders use this measure.
The FY2027 Bridge
On the Q3 call CFO Jochen Schmitz put the underlying FY2026 EPS base at about €2.25 excluding refunds, GuruFocus reported. He listed three drags for FY2027. Tax normalisation and higher interest each cost about €0.05. Separation costs take a similar amount.
Net debt is about €12bn. Siemens Healthineers leverage fell to 2.8 times EBITDA from 3.1 times, according to the same GuruFocus summary.
Mid-Term Targets From the 2025 Capital Markets Day
| Target (FY2027 to FY2030) | Level |
|---|---|
| Group revenue growth | 5% to 7% a year |
| Imaging plus Precision Therapy growth | 6% to 9% a year |
| Adjusted EPS growth | Double digit a year |
| Cash conversion | 0.8 to 0.9 |
| Net debt to EBITDA | 2.5x within two years |
Source: Siemens Healthineers Capital Markets Day 2025 release. Forecasts are not a reliable indicator of future performance.
Siemens Healthineers Q4 Results Preview
The Siemens Healthineers earnings date is Thursday 5 November 2026, with an analyst call the same day. The release will also give the Siemens Healthineers fiscal 2027 outlook.
| Item | Last reading or guide | What markets often compare |
|---|---|---|
| Q4 adjusted EPS | Consensus €0.69 (Q4 FY2025 actual €0.68) | Beat or miss against consensus |
| FY2026 adjusted EPS | Guide €2.35 to €2.45 | Where in the range the year ends |
| FY2026 revenue growth | Guide 3.5% to 4.0% | Whether a third cut is avoided |
| Imaging | Guided to high single-digit growth in Q4 | Order intake and book-to-bill |
| Diagnostics | Guided to a mid single-digit decline | Pace of the decline and the carve-out |
| FY2027 outlook | Underlying EPS base about €2.25 | Size of FX and separation headwinds |
Source: TipRanks earnings, GuruFocus, Q3 release. Forecasts are not a reliable indicator of future performance.
Results days have moved the shares sharply in the past year. The stock fell 6.6% on the day of the FY2025 results, as Börsen-Zeitung reported. It also fell after the Q2 cut in May.
The Diagnostics Carve-Out Question
Management is preparing a Siemens Healthineers diagnostics carve-out. On the Q2 call in May, Montag described the unit this way. "We can be an owner of this business, but we don't have to be an owner of this business," he said, Reuters reported. Any update on 5 November could matter for the valuation.
Siemens Healthineers Price Target and Analyst Ratings
The latest Siemens Healthineers analyst rating count on TipRanks shows seven Buy and three Hold ratings over three months, with zero Sell ratings.
| Broker | Rating | Siemens Healthineers price target | Date | Gap to €41.86 |
|---|---|---|---|---|
| J.P. Morgan | Overweight | €57.40 | 6 Aug 2026 | +37.1% |
| Jefferies | Buy | €50.00 | 28 Sep 2026 | +19.4% |
| RBC | Outperform | €48.00 | 16 Oct 2026 | +14.7% |
| Barclays | Overweight | €47.50 | 3 Aug 2026 | +13.5% |
| Citi | Buy | €47.00 | 13 Oct 2026 | +12.3% |
| ODDO BHF | Outperform | €45.00 | 14 Oct 2026 | +7.5% |
| Bernstein | Outperform | €44.50 | 4 Aug 2026 | +6.3% |
| Berenberg | Hold | €40.00 | 11 Sep 2026 | -4.4% |
| Deutsche Bank | Hold | €39.00 | 5 Oct 2026 | -6.8% |
| UBS | Neutral | €38.00 | 3 Aug 2026 | -9.2% |
| Morgan Stanley | Equal-weight | €37.00 | 23 Jun 2026 | -11.6% |
Source: TipRanks, Börse Express, Goldesel, trading-treff. Gaps are our calculation. Forecasts are not a reliable indicator of future performance.
Consensus Summary
| Measure | Value |
|---|---|
| Siemens Healthineers consensus price target (TipRanks) | €45.71 |
| Highest target | €57.40 |
| Lowest target (three months) | €38.00 |
| Implied gap to average | about +9.2% |
| FY2026 revenue estimate (MarketScreener) | €23.6bn |
| FY2027 revenue estimate (MarketScreener) | €25.0bn |
Source: TipRanks, MarketScreener. Forecasts are not a reliable indicator of future performance.
Price targets often change after results. The spread from €37 to €57.40 shows how far views differ on the spin-off and on Diagnostics.
Siemens Healthineers Technical Analysis
Chart analysts at stock3 said in mid-October that the long downtrend may have ended near the May low. The stock broke a trend line from spring 2025 in mid-August, according to stock3.
Siemens Healthineers Support and Resistance
| Level | Price | Why it matters |
|---|---|---|
| R3 | €47.26 to €49.71 | 2026 high and 52-week high |
| R2 | €44.92 | 2025 close, the break-even mark for 2026 |
| R1 | €42.00 to €42.05 | End-February close and 22 October intraday high |
| Pivot | €41.40 | 23 October day low |
| S1 | €39.40 | Former interim high, now broken |
| S2 | about €38.0 to €39.1 | Area of the 200-day and 50-day averages |
| S3 | about €37 | Post-breakout retest zone |
| S4 | €33 to €35 | May to July base |
| S5 | about €32.8 | May 2026 low |
Source: stock3, Stooq, Stockopedia. Moving-average levels are implied from published percentages. Past performance is not a reliable indicator of future results.
Moving Averages and Momentum
The price sits above both the 50-day and the 200-day moving averages, based on Stockopedia data. Implied values suggest the 50-day line has crossed above the 200-day line at some point since late July. Traders often call that a golden cross.
A rise of about 10% in a month can leave a stock stretched in the short term. That is an inference, since a current RSI reading was unavailable. The Admirals guide to the moving average indicator explains these signals.
Siemens Healthineers Stock Forecast 2026: Illustrative Scenarios
The scenarios below are illustrative. They show how markets could react to different outcomes. They are not predictions.
| Scenario | Possible trigger | Levels markets may watch |
|---|---|---|
| Positive | Q4 beat, FY2027 EPS guide at or above €2.40, orderly spin-off terms on 12 November | A break of €42 could bring €44.92 into view, then about €47.3 |
| Base | Results in line, FY2027 EPS roughly flat at €2.30 to €2.40 | A range of about €38 to €45 |
| Negative | Weaker Diagnostics or China, a cautious FY2027, medtech tariffs, early Siemens share sales | A return to €39.4 or the €38 area, then €37 and the €33 to €35 base |
Source: GuruFocus, stock3. Illustrative only. Forecasts are not a reliable indicator of future performance.
Each path carries risk. A good Q4 can still meet selling if the spin-off news disappoints a week later.
Key Risks for SHL Shareholders
- Spin-off supply could weigh on the price as new holders decide whether to keep their shares.
- Siemens could sell part of its remaining stake after the spin-off.
- Diagnostics revenue could keep falling, with China the main drag.
- Tariff refunds are one-off and the Section 232 outcome is still pending.
- A strong euro lowers the value of US revenue.
- About €14.3bn owed to the Siemens Group needs refinancing.
- Revenue guidance was cut twice in FY2026, which may weigh on trust in new targets.
Upside drivers exist as well. Photon-counting CT is about 30% of CT order volume, the CEO said on the Q3 call, according to GuruFocus. The new Accela radiotherapy system launched in September, though it still awaits US clearance, as the Accela press release shows.
Dividend and Income Facts
The company paid €1.00 per share for FY2025, up from €0.95 a year earlier, as its Q4 FY2025 release showed. At €41.86 that equals a trailing yield of about 2.4%, before taxes and costs, which may vary. The Capital Markets Day plan targets a stable or rising dividend. Dividends are never certain and can be cut.
The dividend proposal for FY2026 may come with the full-year results on 5 November, as the FY2025 proposal did in the Q4 FY2025 release.
Key Dates for Siemens Healthineers Stock
| Date | Event |
|---|---|
| Mondays | Weekly buyback report |
| 5 Nov 2026 | Q4 and FY2026 results, FY2027 outlook |
| 12 Nov 2026 | Siemens AG annual results and spin-off update |
| 29 Jan 2027 | Latest end of the €230m buyback |
| 4 Feb 2027 | Q1 FY2027 results |
| 11 Feb 2027 (to be confirmed) | Siemens AG AGM vote on the spin-off |
| 18 Feb 2027 | Siemens Healthineers AGM |
Source: Siemens Healthineers financial calendar, Siemens AG financial calendar, Deutsche Börse / EQS.
The Admirals economic calendar lists macro releases that may move European equities in the same weeks.
How to Trade Siemens Healthineers Stock: Approaches and Risks Around Earnings
Volatility tends to rise around results days. This section describes common approaches and their risks. It does not recommend any trade.
Common Ways to Gain Exposure
| Approach | How it works | Main risk |
|---|---|---|
| Buying shares | You own the shares and may receive dividends | You may lose part or all of the amount invested |
| Share CFDs | You trade on price moves with leverage, long or short | Leverage magnifies losses as well as gains |
| DAX index CFDs | You trade the wider German market, of which SHL is one member | Index moves may differ from SHL |
Source: Admirals guide to CFD trading.
Siemens Healthineers is a member of the DAX, as its IR share page states. The Admirals guide to DAX trading covers the index side.
Admirals offers CFDs on shares, Forex, indices and commodities, as well as ETFs and shares. Details of the share CFDs range are on the product page. Check the contract specifications to see whether a given stock is available. Share dealing is available through Invest.MT5, and trading is available on MetaTrader 5.
What Traders Often Watch
- Traders often check the consensus EPS before the release.
- Many compare the new outlook with the CMD targets.
- Some reduce position size before results to manage risk.
- Others wait for the first hour of trading after the release.
- Stop-loss orders are a common tool, although gaps can skip past them.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
A demo account lets you practise with virtual funds. Results on a demo account may differ from live trading.
Summary
Siemens Healthineers enters its Q4 report with the stock 6.8% lower for 2026 and about 28% above the May low. The Q4 numbers on 5 November and the Siemens update on 12 November are the near-term markers. The spin-off vote in February 2027 is the larger structural event. Analyst views remain split. Upside and downside scenarios both stay open.
Frequently Asked Questions
What is the Siemens Healthineers share price?
The stock closed at €41.86 on Xetra on 23 October 2026, down 6.8% for the year so far.
When does Siemens Healthineers report Q4 results?
Siemens Healthineers reports Q4 and full-year FY2026 results on 5 November 2026, together with its FY2027 outlook.
Why is Siemens Healthineers stock down in 2026?
Two cuts to the revenue outlook weighed on the shares. Weak Diagnostics and spin-off worries added pressure.
Who owns Siemens Healthineers stock?
Siemens AG owns about 67%. After the planned spin-off, its stake would fall to about 37% of the shares.
What is the Siemens Healthineers spin-off?
Siemens plans to transfer 30% of Healthineers shares directly to its own shareholders, subject to a vote in February 2027.
Does Siemens Healthineers still make ultrasound systems?
Yes, for procedures. It stopped selling general-imaging systems on 12 October 2026 and keeps cardiovascular and intracardiac products.
What is the Siemens Healthineers consensus price target?
TipRanks shows an average target of €45.71, ranging from €38 to €57.40. Analyst targets are opinions and may change.
Is the Siemens Healthineers buyback for cancellation?
The company buys shares for employee programmes and share-based pay. It had bought 3.47m shares by 11 October.
Some of the content on this page was created with the help of automated tools. All final text has been reviewed by Admirals and is under its editorial responsibility.
The given data provides additional information regarding all analysis, estimates, prognosis, forecasts, market reviews, weekly outlooks or other similar assessments or information (hereinafter “Analysis”) published on the websites of Admirals investment firms operating under the Admirals trademark (hereinafter “Admirals”) Before making any investment decisions please pay close attention to the following:
- This is a marketing communication. The content is published for informative purposes only and is in no way to be construed as investment advice or recommendation. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and that it is not subject to any prohibition on dealing ahead of the dissemination of investment research.
- Any investment decision is made by each client alone whereas Admirals shall not be responsible for any loss or damage arising from any such decision, whether or not based on the content.
- With view to protecting the interests of our clients and the objectivity of the Analysis, Admirals has established relevant internal procedures for prevention and management of conflicts of interest.
- The Analysis is prepared by an analyst (hereinafter “Author”). The Author Admirals is an employee /a contractor for Admirals. This content is a marketing communication and does not constitute independent financial research.
- Whilst every reasonable effort is taken to ensure that all sources of the content are reliable and that all information is presented, as much as possible, in an understandable, timely, precise and complete manner, Admirals does not guarantee the accuracy or completeness of any information contained within the Analysis.
- Any kind of past or modelled performance of financial instruments indicated within the content should not be construed as an express or implied promise, guarantee or implication by Admirals for any future performance. The value of the financial instrument may both increase and decrease and the preservation of the asset value is not guaranteed.
- Leveraged products (including contracts for difference) are speculative in nature and may result in losses or profit. Before you start trading, please ensure that you fully understand the risks involved.
Sources
- Siemens Healthineers AG (SHL.DE) quote, Stooq, accessed 26 October 2026.
- Siemens Healthineers dates and quote, MarketScreener, accessed 26 October 2026.
- Share information, Siemens Healthineers, accessed 26 October 2026.
- Financial calendar, Siemens Healthineers, accessed 26 October 2026.
- Q4 FY2025 results press release, Siemens Healthineers, accessed 26 October 2026.
- Siemens Healthineers cuts 2026 outlook, Reuters via MarketScreener, accessed 26 October 2026.
- Q3 FY2026 Earnings Release and Financial Results, Siemens Healthineers, accessed 26 October 2026.
- Q3 2026 earnings call highlights, GuruFocus, accessed 26 October 2026.
- Medical device industry watches Section 232 deadlines, MichBio, accessed 26 October 2026.
- Siemens Healthineers Aktie auf neuem Tief, Börse Express, accessed 26 October 2026.
- 52-Wochen-Tief bei 32,84 Euro, Börse Express, accessed 26 October 2026.
- ODDO BHF senkt Kursziel, trading-treff, accessed 26 October 2026.
- SHL.DE historical prices, Yahoo Finance, accessed 26 October 2026.
- Siemens plans to deconsolidate Siemens Healthineers, Börsengeflüster newswire, accessed 26 October 2026.
- Spin-off timeline press release, Siemens AG, accessed 26 October 2026.
- Siemens macht Fortschritte bei Abspaltung von Healthineers, VZ / AWP, accessed 26 October 2026.
- Financial calendar, Siemens AG, accessed 26 October 2026.
- Käufe trotz Kurszielkappung, finanztrends, accessed 26 October 2026.
- Siemens Healthineers Sharpens Ultrasound to Focus on the Future of Procedural Imaging, Siemens Healthineers, accessed 26 October 2026.
- Ultraschall fokussiert auf Therapiebildgebung, trading-treff, accessed 26 October 2026.
- Share buyback announcement, Deutsche Börse / EQS, accessed 26 October 2026.
- Buyback 4th interim report, Siemens Healthineers, accessed 26 October 2026.
- Buyback 7th interim report, Siemens Healthineers, accessed 26 October 2026.
- 3,4 Millionen Aktien seit Juni zurückgekauft, finanztrends, accessed 26 October 2026.
- Capital Markets Day 2025 press release, Siemens Healthineers, accessed 26 October 2026.
- DE:SHL earnings, TipRanks, accessed 26 October 2026.
- Healthineers brechen nach enttäuschendem Ausblick ein, Börsen-Zeitung, accessed 26 October 2026.
- DE:SHL forecast, TipRanks, accessed 26 October 2026.
- JPMorgan hebt Ziel auf 57,40 Euro, Börse Express, accessed 26 October 2026.
- RBC hebt Kursziel auf 48 Euro, Goldesel, accessed 26 October 2026.
- Siemens Healthineers quote, MarketScreener UK, accessed 26 October 2026.
- Siemens Healthineers: Aktie auf dem Silbertablett, stock3, accessed 26 October 2026.
- SHL share price, Stockopedia, accessed 26 October 2026.
- Accela launch press release, Siemens Healthineers, accessed 26 October 2026.
